By Jeff Stevens, CEO and co-founder of Psyched Wellness

Psychedelics have made their comeback. More than 40 years after the war on drugs shut down all mainstream applications of psilocybin and others, the space is blooming with hope and promise again. We see states in the U.S. adopting and designing laws and regulations that will facilitate the spread of psychedelic therapies. 

There is also a worldwide shift that is hard to ignore: earlier this year, Australia became the first country to recognize several psychedelic compounds as legal for therapy-resistant depression and PTSD. Other nations, Brazil, for instance, have long been pioneers in embracing practices and substances, including psilocybin, most commonly found in “magic mushrooms” or even DMT, the compound found in ayahuasca brews.

Research communities are now expanding the scope of their studies around psychedelics, exploring areas outside psychiatry. Arizona is about to become the first state to sponsor controlled clinical trials of whole psilocybin mushrooms as a recently introduced bill aims to expand research into areas like the treatment of long COVID, among others. These are strong indicators we still don’t know the full potential of these drugs.

And there are other product segments worth paying …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.